AU2018317865B2 - Polymorphic form of TG02 - Google Patents

Polymorphic form of TG02 Download PDF

Info

Publication number
AU2018317865B2
AU2018317865B2 AU2018317865A AU2018317865A AU2018317865B2 AU 2018317865 B2 AU2018317865 B2 AU 2018317865B2 AU 2018317865 A AU2018317865 A AU 2018317865A AU 2018317865 A AU2018317865 A AU 2018317865A AU 2018317865 B2 AU2018317865 B2 AU 2018317865B2
Authority
AU
Australia
Prior art keywords
cancer
patient
citrate
inhibitor
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018317865A
Other languages
English (en)
Other versions
AU2018317865A1 (en
Inventor
Robert K. Mansfield
Tracy PARROTT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cothera Bioscience Inc
Original Assignee
Cothera Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cothera Bioscience Inc filed Critical Cothera Bioscience Inc
Publication of AU2018317865A1 publication Critical patent/AU2018317865A1/en
Assigned to Cothera Bioscience, Inc. reassignment Cothera Bioscience, Inc. Request for Assignment Assignors: TRAGARA PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2018317865B2 publication Critical patent/AU2018317865B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2018317865A 2017-08-18 2018-08-17 Polymorphic form of TG02 Active AU2018317865B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762547157P 2017-08-18 2017-08-18
US62/547,157 2017-08-18
PCT/US2018/000264 WO2019035985A1 (en) 2017-08-18 2018-08-17 POLYMORPHIC FORM OF TG02

Publications (2)

Publication Number Publication Date
AU2018317865A1 AU2018317865A1 (en) 2020-03-19
AU2018317865B2 true AU2018317865B2 (en) 2023-03-16

Family

ID=65359869

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018317865A Active AU2018317865B2 (en) 2017-08-18 2018-08-17 Polymorphic form of TG02

Country Status (14)

Country Link
US (4) US10544162B2 (enExample)
EP (2) EP4364741A3 (enExample)
JP (1) JP7250764B2 (enExample)
KR (1) KR102758037B1 (enExample)
CN (1) CN111372934B (enExample)
AU (1) AU2018317865B2 (enExample)
CA (1) CA3073270A1 (enExample)
ES (1) ES2977589T3 (enExample)
IL (1) IL272697B2 (enExample)
MX (1) MX2020001875A (enExample)
RU (1) RU2020111019A (enExample)
SG (1) SG11202001441WA (enExample)
TW (1) TWI785098B (enExample)
WO (1) WO2019035985A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2749025C2 (ru) 2016-03-24 2021-06-03 Трагара Фармасьютикалз, Инк. Лечение рака при помощи tg02
RU2020111019A (ru) 2017-08-18 2021-09-20 Трагара Фармасьютикалз, Инк. Полиморфная форма tg02
JP7684910B2 (ja) * 2019-04-22 2025-05-28 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 小児対象において神経膠腫を治療するためのｔｇ０２の使用
CN110664760B (zh) * 2019-10-28 2020-10-23 浙江大学 一种负载vegfr靶向抑制剂的药物载体及其制备方法和应用
WO2024031406A1 (en) * 2022-08-10 2024-02-15 Xiang Li Idh mutations as biomarkers for zotiraciclib therapy
CN115429793A (zh) * 2022-08-15 2022-12-06 复旦大学附属中山医院 一种化合物在制备治疗肝细胞癌药物中的应用
CN115305251B (zh) * 2022-08-30 2023-06-27 中国农业科学院北京畜牧兽医研究所 Ap2-mybl2分子模块在调控原花色素生物合成中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130150378A1 (en) * 2010-02-05 2013-06-13 Robert K. Mansfield Solid state forms of macrocyclic kinase inhibitors

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL63907A0 (en) 1980-09-24 1981-12-31 Cetus Corp Diagnostic method and antibody probe for use therein
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
ATE53862T1 (de) 1982-01-22 1990-06-15 Cetus Corp Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel.
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
ES2282133T3 (es) 1999-08-24 2007-10-16 Medarex, Inc. Anticuerpos frente a la ctla-4 humano y sus usos.
AU2003213054A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
KR20070114753A (ko) * 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2007058628A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Heteroalkyl linked pyrimidine derivatives
JP5496877B2 (ja) 2007-04-16 2014-05-21 アッヴィ・インコーポレイテッド ７−置換インドールＭｃｌ−１阻害薬
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
GB0806652D0 (en) 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010027423A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
TWI605828B (zh) 2008-12-09 2017-11-21 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
US20120148661A1 (en) * 2009-04-15 2012-06-14 Poniard Pharmaceuticals, Inc. High bioavailability oral picoplatin anti-cancer therapy
JP4965623B2 (ja) 2009-09-30 2012-07-04 インターナショナル・ビジネス・マシーンズ・コーポレーション 所定のソフトウェアの実行パラメータを入力フィールドへ入力することを支援するための方法、システム、およびプログラム
WO2011103016A2 (en) 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
JP2013525283A (ja) 2010-04-06 2013-06-20 フレッド ハッチンソン キャンサー リサーチ センター ＭＹＣ駆動型腫瘍細胞の成長および／または増殖を阻害するためのカゼインキナーゼ１εアイソフォームのインヒビターを同定および使用するための方法
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US8895245B2 (en) 2010-09-10 2014-11-25 Epizyme, Inc. Inhibitors of human EZH2 and methods of use thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
US20130071403A1 (en) 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
KR20140082742A (ko) 2011-09-30 2014-07-02 글락소스미스클라인 엘엘씨 암을 치료하는 방법
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
PT2825161T (pt) 2012-03-12 2019-04-29 Epizyme Inc Inibidores de ezh2 humana e métodos de uso dos mesmos
WO2013173223A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
US10513540B2 (en) 2012-07-31 2019-12-24 The Brigham And Women's Hospital, Inc. Modulation of the immune response
HRP20191814T1 (hr) 2012-10-15 2019-12-27 Epizyme, Inc. Načini liječenja karcinoma
KR101858913B1 (ko) 2013-02-21 2018-05-16 화이자 인코포레이티드 고체 형태의 선택적인 cdk4/6 억제제
IL240838B (en) 2013-03-15 2022-09-01 Glaxosmithkline Ip Dev Ltd Anti-3–lag binding proteins
BR112016005303A2 (pt) 2013-09-11 2017-09-12 Medimmune Ltd anticorpos anti-b7-h1 para tratamento de tumores
US20150250853A1 (en) 2014-03-07 2015-09-10 University Health Network Methods and compositions for modifying the immune response
UY36032A (es) 2014-03-14 2015-10-30 Novartis Ag Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
NZ723859A (en) 2014-03-14 2023-01-27 Servier Lab Pharmaceutical compositions of therapeutically active compounds and their uses
RU2749025C2 (ru) 2016-03-24 2021-06-03 Трагара Фармасьютикалз, Инк. Лечение рака при помощи tg02
RU2020111019A (ru) 2017-08-18 2021-09-20 Трагара Фармасьютикалз, Инк. Полиморфная форма tg02

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130150378A1 (en) * 2010-02-05 2013-06-13 Robert K. Mansfield Solid state forms of macrocyclic kinase inhibitors

Also Published As

Publication number Publication date
US20190055263A1 (en) 2019-02-21
AU2018317865A1 (en) 2020-03-19
RU2020111019A (ru) 2021-09-20
JP2020531463A (ja) 2020-11-05
WO2019035985A1 (en) 2019-02-21
US20240254142A1 (en) 2024-08-01
EP4364741A2 (en) 2024-05-08
EP4364741A3 (en) 2024-07-03
ES2977589T3 (es) 2024-08-27
US10544162B2 (en) 2020-01-28
EP3668876A1 (en) 2020-06-24
IL272697B1 (en) 2023-08-01
TWI785098B (zh) 2022-12-01
US20240254141A1 (en) 2024-08-01
IL272697B2 (en) 2023-12-01
EP3668876A4 (en) 2021-04-28
KR20200078481A (ko) 2020-07-01
EP3668876B1 (en) 2024-01-24
CN111372934A (zh) 2020-07-03
US12043630B2 (en) 2024-07-23
IL272697A (en) 2020-04-30
KR102758037B1 (ko) 2025-01-22
CN111372934B (zh) 2024-04-26
TW201920199A (zh) 2019-06-01
SG11202001441WA (en) 2020-03-30
CA3073270A1 (en) 2019-02-21
JP7250764B2 (ja) 2023-04-03
US20200262843A1 (en) 2020-08-20
RU2020111019A3 (enExample) 2022-03-18
MX2020001875A (es) 2020-07-29

Similar Documents

Publication Publication Date Title
US20240156824A1 (en) Treatment of cancer with tg02
US20240254141A1 (en) Polymorphic form of tg02 for treating cancer
Ling et al. The prognostic value and molecular properties of tertiary lymphoid structures in oesophageal squamous cell carcinoma
EP3430171B1 (en) Detection and treatment of anti-pd-1 therapy resistant metastatic melanomas
JP2022027788A (ja) 固形腫瘍を有する患者をクラス分けするための方法
CN101932724B (zh) 胃肠癌的增生标签及预后
ES2491222T3 (es) Marcadores de expresión génica para el pronóstico de cáncer colorrectal
Zhang et al. Identification of a Novel ECM Remodeling Macrophage Subset in AKI to CKD Transition by Integrative Spatial and Single‐Cell Analysis
MX2010008572A (es) Metodos de diagnostico y tratamiento de enfermedades mediadas por poli(adp-ribosa) polimerasa.
US20220185886A1 (en) Methods for identifying biomarkers to predict treatment response
JP2024541909A (ja) 乳がんの腫瘍微小環境タイプ
HK40106713A (en) Polymorphic form of tg02
CA3018875C (en) Treatment of cancer with tg02
HK40025378A (en) Polymorphic form of tg02
HK40025378B (en) Polymorphic form of tg02
US20240139175A1 (en) Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor
CN106947820B (zh) Vcan在结肠腺癌诊治中的用途
HK1261788A1 (en) Treatment of cancer with tg02
HK1261788B (en) Treatment of cancer with tg02
Kurimoto et al. MYC/BCL2 double-hit Lymphoma in a patient with rheumatoid arthritis associated with methotrexate treatment
US20240379188A1 (en) Techniques for single sample expression projection to an expression cohort sequenced with another protocol
KR20190079801A (ko) 방사선 치료에 대한 직장암의 예후 예측용 조성물
金村宙昌 et al. The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC
Jani et al. Circulating neoantigen-and viral oncoprotein–specific CD8+ T cells share a transcriptional signature
WO2025193774A1 (en) Methods of identifying and treating an immune poor cancer

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: COTHERA BIOSCIENCE, INC.

Free format text: FORMER APPLICANT(S): TRAGARA PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)